Vor Biopharma Chief Development Officer Qing Zuraw departs Dec 31; gets $565K severance + consulting

Vor Biopharma Inc.

Dr. Qing Zuraw, Chief Development Officer, resigned effective Dec 31, 2025 to pursue other opportunities.
Separation pay of $565,000 (12 months) plus $115,724 prorated 2025 target bonus; retains $100K signing bonus.
All unvested stock options and RSUs forfeited (no vesting before one-year anniversary).
Company expects to enter a consulting arrangement with Zuraw for Q1 2026 to assist transition.
Separation includes 12-month non-compete, non-disparagement, and standard confidentiality covenants.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.